ImmuneSensor Therapeutics has begun dosing in its Phase 1 clinical trial for its primary cGAS inhibitor candidate, IMSB301.

Phanes Therapeutics has reported that the initial patient has been treated in a clinical trial involving PT886 alongside KEYTRUDA® (pembrolizumab).

Blue Earth Therapeutics pushes forward with the clinical development of Lutetium (177Lu) rhPSMA-10.1 injection, showing encouraging Phase 1 results.

Astellas and AviadoBio have signed a unique option and licensing deal for the gene therapy AVB-101, aimed at treating frontotemporal dementia and other conditions.

Merck's KEYTRUDA® (pembrolizumab) achieved its main goal of event-free survival (EFS) as a perioperative treatment for patients with resected, locally advanced head and neck squamous cell carcinoma.

Sage Therapeutics Unveils Key Findings from Phase 2 LIGHTWAVE Trial of Dalzanemdor (SAGE-718) for Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Patients.

Pierre Fabre Laboratories and Scorpion Therapeutics have begun a Phase I/II clinical trial, dosing the first patient with PFL-241/STX-241.

Hiro-LS, PatSnap's biopharmaceutical AI model, integrates the proprietary PharmaGPT, a large-scale AI model with 70 billion parameters.

KaliVir Immunotherapeutics administers initial dose in Phase 1/1b trial for VET3-TGI targeting advanced solid tumors.

Oct 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

AstraZeneca enhances its heart health portfolio by securing a deal for a new pre-clinical therapy to lower lipids.

Intellia Therapeutics has begun the HAELO Phase 3 trial for NTLA-2002, a potential CRISPR gene editing treatment for hereditary angioedema.